Not Tagged
Not Tagged
['tnbc']
great data #asco2022 on her3-dxt and sacituzumab in er pos and tnbc. so how do we pick which agent to use? field becoming crowded. and with similar payload doubt one adc would work after progression on the other.
Oncologist and tennis player